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1.1          Literature Review 
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ABSTRACT 
Purpose 
Evaluate the outcomes of men with Gleason 7 prostate cancer followed on active surveillance in 
the published literature. 
Methods 
We conducted a PubMed search including variations of the terms prostate cancer, active 
surveillance, and Gleason 7 disease.  We supplemented this search with a detailed review of 
cited references.  We analyzed and critiqued relevant articles for study design, sample size, 
eligibility criteria, outcomes, length of follow-up, data sources, statistical methods, and risk of 
bias.  
Results 
After title and abstract review of 125 articles identified by our PubMed search and the addition 
of four articles discovered during our detailed References review, we identified five relevant 
studies.  Conclusions from these studies are different, as are the measures, outcomes, and study 
inclusion criteria.  Risk of bias is high and generalizability is severely limited. 
Conclusion 
Little reliable data about the safety of following men with Gleason 7 prostate cancer on active 
surveillance can be extrapolated from published studies.   
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INTRODUCTION 
Prostate cancer is the most commonly diagnosed cancer among men in the developed world.
1
  
In the United States this year, an estimated 220,800 men will receive a new diagnosis of prostate 
cancer and 27,540 will die of the disease.
2
  Among men newly diagnosed with prostate cancer, 
approximately 90% will pursue definitive treatment (surgery or radiation therapy)
3, 4
 and the 
majority will experience at least one long-term adverse effect due to this treatment.
5
  The 
disease’s high incidence, treatment morbidity, and long natural history have provoked extensive 
public health discussions about overdiagnosis and overtreatment.   
To reduce the overtreatment of low-risk prostate cancer (Appendix A, Table 1.1),
6-8
 
active surveillance protocols began in the late 1990’s.  On protocol, enrolled patients with low-
risk prostate cancer undergo biannual PSA testing, an annual digital rectal exam, and a repeat 
prostate biopsy as frequently as every 12 months.  Worsening PSA kinetics, progression of 
clinical stage on rectal exam, or changing biopsy characteristics trigger definitive treatment. The 
reported mortality for prostate cancer is <1% among men with low-risk prostate cancer on active 
surveillance protocols with long-term follow-up.
9
   
The qualifying criteria for intermediate-risk prostate cancer (Appendix A, Table 1.1) 
includes Gleason 7 disease (Appendix A, Table 1.2), which, is the most common Gleason sum 
on prostate biopsy.
10
  With the objective of further mitigating prostate cancer overtreatment, we 
examined the literature for studies including men with Gleason 7 disease followed on active 
surveillance.   
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METHODS 
Search Strategy 
 To identify published studies addressing our question of how men with Gleason 7 
prostate cancer fare on active surveillance, we conducted an advanced PubMed search 
combining MeSH and text word terms on June 9, 2015 following consultation with a Cancer 
Information Librarian in the Health Sciences Library at the University of North Carolina, Chapel 
Hill.  We did not apply any limitations on language or publication date.  Our specific search 
strategy was: 
(Prostatic Neoplasms[mesh] OR prostatic neoplasms[tw] OR prostatic neoplasm[tw] OR 
Prostate Cancer[tw] OR Prostate Cancers[tw] OR Cancer of the Prostate[tw] OR 
Prostatic Cancers[tw] OR Prostatic Cancer[tw]) AND active surveillance[tw] OR 
surveillance[tw]) AND (Gleason 7[tw] OR Gleason Score 7[tw] OR Gleason 
Score=7[tw] OR Gleason Score<7 OR Gleason score 3+4[tw]) 
The search yielded 125 articles for review.  We supplemented this search with a detailed 
examination of cited references from the retrieved articles, which yielded an additional 4 relevant 
studies for review.     
Study Selection 
We reviewed the titles and abstracts of all articles to identify the publications most likely 
to address the study question.  We further reviewed the Methods and Results section of 10 
articles to determine relevance to our study question.  Our inclusion criteria required the articles 
review clinically- or oncologically-significant outcomes for men with localized Gleason 7 
prostate cancer followed on active surveillance.  Clinically- or oncologically-significant 
outcomes included Gleason score progression on repeat biopsy, progression to radical treatment, 
time to radical treatment, prostate cancer specific survival, and overall survival.  We excluded 
prostate cancer review articles and expert opinion pieces, choosing to focus our review upon 
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original research.  We excluded studies of men with localized prostate cancer followed 
exclusively on watchful waiting protocols.  In contrast to active surveillance, which involves 
close monitoring and administration of curative treatment in response to disease progression 
detected by PSA kinetics, a change in disease characteristics identified on repeat biopsy, or a 
palpable change on digital rectal exam, watchful waiting advises androgen deprivation when 
prostate cancer becomes symptomatic,
11
 most commonly from osseous metastases or urinary 
obstruction.
12
  The objective of active surveillance is selective delayed intervention with curative 
intent among men meeting specific disease criteria, whereas symptom palliation is the goal in 
watchful waiting.  For this reason, expectations for prostate cancer-specific survival and overall 
survival are quite different between men followed on modern active surveillance protocols and 
men followed on watchful waiting.   
Data Abstraction and Quality Assessment 
 We analyzed the articles relevant to our study question for the following details: study 
design, sample size, study outcome(s), length of follow-up, study participants and eligibility 
criteria, relevant demographic data including age and baseline PSA, data sources, measurement, 
statistical methods, main results, and any study funding or author conflicts of interest.  
 Extrapolating key study quality assessment items from the STROBE criteria,
13
 we graded 
each study based upon the strength of the design, study size (with a focus upon the number of 
men with Gleason 7 prostate cancer included in the study), study outcome data, length of follow-
up, and risk of bias.  Each study received a grade of 1 (lowest) to 3 (highest) in each of these five 
categories, for a total score of 3-15.  For study design: case series received 1 point, single cohort 
studies received 2 points, and cohort studies with a control group received 3 points.  For study 
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size: studies with <50 men with Gleason 7 prostate cancer received 1 point, 50-100 men with 
Gleason 7 disease received 2 points, and studies with >100 men with Gleason 7 prostate cancer 
received 3 points.  For oncological relevance and evaluation of study outcomes: studies limited 
to progression to radical treatment received 1 point, studies of intermediate outcomes such as 
biochemical recurrence among those receiving curative intervention received 2 points, and 
studies evaluating overall or prostate-cancer specific survival received 3 points.  Length of 
follow-up was graded: 1 point for <3 years follow-up, 2 points for ≥3 years but <6 years follow-
up, and 3 points for ≥6 years of follow-up.  Finally, points were inversely assigned in relation to 
the perceived risk of bias within the study: studies at the highest risk of bias received 1 point, 
studies with an intermediate risk of bias received 2 points, and studies with little perceived bias 
received 3 points.   
RESULTS 
After title and abstract review of 125 articles identified by our PubMed search and the 
addition of four articles identified during our detailed References review, we identified a total of 
seven relevant articles
14-20
  (Appendix B, Figure 1.1).  Upon comprehensive review of the seven 
relevant articles, three captured the same active surveillance source population from the 
University of Toronto.
14, 15, 18
  Accordingly, we chose the most recent publication from this group 
for data abstraction and quality assessment, as this publication captured the longest clinical 
follow-up period.
18
  In total, we performed complete data abstraction and quality assessment for 
five studies
16-20
 (Appendix C, Tables 1.1 and 1.2).  The studies varied significantly in overall 
quality, ranging from a score of 6 to 13 on a 15-point scale designed for grading observational 
studies.
13
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  The included studies reported various outcomes of men with Gleason 7 prostate cancer 
followed over time on active surveillance.
7, 17-20
  The study designs, measures, population size, 
length of follow-up, evaluated outcomes, and findings are quite variable.   
Three studies report findings from single institution prospective active surveillance 
databases with detailed measures and triggers for curative treatment.
17, 18, 20
  Of these three cohort 
studies, only Cooperberg et al.’s study of men with intermediate-risk prostate cancer followed on 
active surveillance at the University of California, San Francisco provides a control group.
17
  The 
remaining studies from the University of Toronto
18
 and Royal Marsden Hospital in the United 
Kingdom
20
 are single cohort studies reporting the outcomes of men enrolled on institutional 
active surveillance protocols, a fraction of whom had intermediate risk disease.  The two final 
studies in this review from Stattin et al.
19
 and van den Bergh et al.
16
 include data generated from 
larger studies; within these studies, the authors abstracted data on men with intermediate risk 
disease followed on an uncertain combination of active surveillance and watchful waiting.
16, 19
  
Stattin et al. used data collected during the National Prostate Cancer Register of Sweden Follow-
up Study to retrospectively evaluate the outcomes of men diagnosed with localized prostate 
cancer, some of whom had Gleason 7 disease.
19
  van den Bergh et al. compiled a case series of 
men enrolled in the European Randomized Study of Screening for Prostate Cancer with screen-
diagnosed Gleason 7 disease followed expectantly.
16
 
Despite the large studies from which several of the included articles draw their study 
populations, the number of men with Gleason 7 disease in the studies is small, ranging from 29 
to 93 men.
17, 19
  Follow-up of these small numbers of men ranges from 22 months to 8.2 years.
19, 
20
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Three studies evaluated the oncologically-critical outcomes of overall survival or 
prostate-cancer specific survival.
16, 18, 19
  The first study, van den Bergh et al.’s case series of men 
with Gleason 7 prostate cancer, reported 68% 6-year overall survival and 100% 6-year cancer-
specific survival, leading the authors to suggest that active surveillance might be an option for 
selected patients with screen-detected Gleason 3+4 disease.
16
  The second study, Stattin et al.’s 
study of men with localized prostate cancer from the National Prostate Cancer Register of 
Sweden Follow-up Study, reported that men with intermediate-risk disease followed on 
surveillance were more than twice as likely to die of prostate cancer as were men with low-risk 
disease followed on surveillance (5.2% [95% CI: 3.7-6.9%] vs. 2.4% [95% CI: 1.2-4.1%]).
19
  
While the third study from Klotz et al. at the University of Toronto did not provide specific 
survival data for men with intermediate-risk disease, the study reported that men with Gleason 
3+4 disease were nearly twice as likely to transition from active surveillance to radical treatment 
(OR 1.83 [95%CI: 1.086-3.097]; p=0.0233) compared to men with Gleason ≤6 disease.
18
  The 
remaining two active surveillance cohort studies also evaluated the transition to curative 
treatment.
17, 20
  On univariate analysis, van As et al. identified an association between Gleason 7 
disease and a shorter time to radical treatment in the Royal Marsden active surveillance cohort 
(HR 2.43 [95% CI 1.39-4.25]; p=0.002).  On multivariate analysis adjusted for initial PSA, 
clinical T stage, free/total PSA ratio, PSA density, percent positive cores, number of positive 
scores, prostate volume, and maximum percentage cancer involvement in any core, this 
association was no longer significant.  Finally, in the University of California, San Francisco 
active surveillance cohort, Cooperberg et al. reported that men with intermediate risk disease 
were no more likely to progress to active treatment than men with low-risk disease.
17
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DISCUSSION 
 We identified five studies that include men with Gleason 7 prostate cancer followed on 
active surveillance.  Drawing any conclusions from these studies presents a challenge, as the 
included study populations, length of follow-up, and evaluated outcomes are quite different.  At 
face value, two studies suggest that active surveillance is appropriate for men with Gleason 7 or 
intermediate risk prostate cancer.
16, 17
  In contrast, two studies report that men with Gleason 7 
disease followed on active surveillance do not fare well, with markedly higher rates of prostate-
cancer specific death
19
 and transitions to curative treatment.
18
  The final study reports an 
association between Gleason 7 disease and a shorter time to radical treatment on univariate 
analysis; however, this association loses significance upon multivariate analysis.
20
  The risks of 
various biases and the influence of these biases upon study findings are critical to understand 
before determining whether men with Gleason 7 prostate cancer can be safely followed on active 
surveillance.     
   Of the studies captured in this review, the National Prostate Cancer Register of Sweden 
Follow-up Study provides the highest quality statistical analysis, has the longest follow-up, 
includes the largest number of men with Gleason 7 prostate cancer followed on active 
surveillance, and has the most generalizable study population, including 90% of all patients in 
Sweden 70 years or younger with a low- or intermediate-risk prostate cancer diagnosed from 
January 1, 1997, through December 31, 2002.
19
  The study evaluated the oncologically-critical 
outcomes of prostate-cancer specific mortality and overall survival, concluding that men with 
low-risk prostate cancer may be safely followed on active surveillance.  In contrast, men with 
intermediate-risk disease followed on surveillance were more than twice as likely to die of 
prostate cancer as were men with low-risk disease.   
12 
 
While the study
19
 has multiple strengths, fundamental flaws in study group composition 
and the definition of surveillance used in the research design limit extrapolation of study findings 
to our review question.  The intermediate-risk group defined in the study included men with a 
Gleason score ≤7 and a PSA <20 ng/mL.  In total, this group included 936 men; however, only 
93 of these men had a Gleason score of 7.  Analyses were stratified by risk-level, rather than by 
Gleason score.  The influence of disease aggressiveness (as reflected by the Gleason score) vs. 
total disease burden (as reflected by PSA value) upon the outcomes of men with intermediate 
risk disease followed on active surveillance cannot be determined from the provided data.  
Additionally, an inherent selection bias that affects overall and prostate-cancer specific survival 
exists in this observational cohort, as healthy patients with intermediate-risk prostate cancer were 
likely counseled to undergo curative treatment, whereas men with multiple comorbidities were 
likely encouraged to pursue surveillance or watchful waiting.  The influence of this bias would 
positively skew the magnitude of the study results.  Finally, treatment for men on surveillance in 
this nationwide observational cohort was a mixture of active surveillance and watchful waiting.  
As previously reviewed, prostate cancer-specific survival and overall survival is quite different 
among men on modern active surveillance protocols as compared to men followed on watchful 
waiting.  The ratio of men followed on active surveillance compared to watchful waiting in the 
study population is uncertain.   
 Similar to the National Prostate Cancer Register of Sweden Follow-up Study
19
, van den 
Bergh et al.’s case series of 50 men with screen-detected Gleason 7 prostate cancer also included 
men followed on both active surveillance and watchful waiting.
16
  However, in stark contrast to 
the lower prostate cancer- specific survival rates among intermediate-risk men reported in the 
Swedish study, van den Bergh et al. reported 100% 6-year prostate cancer-specific survival 
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among men with Gleason 7 prostate cancer who were followed expectantly.  No prostate cancer-
specific deaths in a population of men with Gleason 7 disease managed with a mixture of active 
surveillance and watchful waiting is quite remarkable and raises concerns for selection bias.  In 
total, the European Randomized Study of Screening for Prostate Cancer, which is the source 
population for this case series, enrolled 162,387 men in seven European centers.
21
  From four 
participating sites, van den Bergh et al. identified 50 men with Gleason 7 prostate cancer 
followed expectantly.  The authors omit specific information concerning the identification of 
these men and any applied exclusion criteria, which severely hampers interpretation and 
generalizability of the study’s findings. 
 While the studies from Stattin et al.
19
 and van den Bergh et al.
16
 lack uniform follow-up 
for men with Gleason 7 prostate cancer, the remaining studies included in our review follow men 
on single-institution active surveillance protocols with well-defined follow-up measures and 
triggers for curative treatment.
17, 18, 22
  Unfortunately, each study is also plagued by significant 
deficits limiting application to our study question regarding how men with Gleason 7 prostate 
cancer fare on active surveillance. 
 Klotz et al.’s cohort of men on active surveillance at the University of Toronto includes 
72 men with Gleason 3+4 disease followed for a median of 6.8 years.  Unfortunately, while the 
study is well presented and examines the oncologically-critical outcomes of overall survival and 
prostate-cancer specific survival, these outcomes are not stratified by risk group or Gleason 
score.  On univariate logistic regression analysis, men with Gleason 3+4 prostate cancer are 
nearly twice as likely to transition from active surveillance to radical treatment compared to men 
with Gleason ≤6 disease.  Whether this finding would persist on multivariable analysis when 
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adjusted for PSA, clinical stage, age, race, PSA density, or percentage core involvement, is 
uncertain.  This uncertainty limits the generalization of the study’s findings.         
   Cooperberg et. al’s cohort of men on active surveillance at the University of California, 
San Francisco includes 90 men with intermediate-risk disease, though only 29 of these men had 
Gleason 7 disease.
17
  While this is the only study to directly compare the outcomes of men with 
intermediate-risk prostate cancer followed on a well-defined active surveillance protocol to a 
control group of low-risk prostate cancer patients followed on the same active surveillance 
protocol, the authors’ classification of low- and intermediate-risk disease restricts extrapolation 
to our study question.  The authors’ included men with Gleason score 2-6 (Appendix A, Table 
1.2) and CAPRA score 0-2 (Appendix A, Table 1.4) as low-risk and men with Gleason score 7 
and CAPRA score 3-5 as intermediate risk.  By CAPRA score, men with higher volume Gleason 
6 disease fit in the intermediate-risk category and, in fact, compose the majority of the study’s 
intermediate-risk group.  The oncologic acceptability of this classification is debatable.
23, 24
  As a 
result, Cooperberg et al.’s conclusion of no difference in cancer progression, PSA doubling time, 
or progression to active treatment between low- and intermediate-risk men followed on active 
surveillance may not apply specifically to men with Gleason 7 disease. 
          The last prospective active surveillance cohort in our review includes 39 men with 
Gleason 7 prostate cancer followed on protocol at the Royal Marsden Hospital.  van As et al. 
found Gleason 7 disease was associated with a shorter time to radical treatment on univariate 
analysis, though not on multivariate analysis.  With a time-dependent solitary outcome, the 
study’s significant limitation is its 22 month median follow-up, which is far too short to draw 
any generalizable conclusions.  Additionally, the study fails to account for personal preference as 
the reason for discontinuation of active surveillance.  As 20% of men followed on active 
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surveillance transition to curative treatment over time because of personal preferences or 
anxiety,
25
 this is a significant confounder which requires measurement and adjustment.        
CONCLUSION 
We identified five studies that included men with Gleason 7 prostate cancer followed on 
active surveillance.  Conclusions from these studies are different, as are the measures, outcomes, 
and study inclusion criteria.  Weighing the risk of bias and generalizability of these studies, little 
reliable data about the safety of following men with Gleason 7 prostate cancer on active 
surveillance can be extrapolated.  Further research, with more rigorous study designs and 
statistical analyses, is needed before offering active surveillance as a management strategy to 
men with Gleason 7 disease.  
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1.2          Appendix A: Prostate Cancer Risk Stratification 
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Table 1.1: Most widely used risk strata for newly diagnosed prostate cancer.
6-8
   
Risk Category PSA Gleason Score Clinical Exam 
Low ≤ 10 ng/mL       and  ≤ 6
*
          and T1c, T2a
^
 
Intermediate PSA > 10 to 20 ng/mL   or 7 (3+4 or 4+3)
 *
     or T2b
^
 
High PSA > 20 ng/mL     or 8-10
*
           or T2c or higher
^
 
 
*
Refer to Table 1.2 
^
Refer to Table 1.3 
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Table 1.2: Gleason scoring for prostate carcinoma.
26
 
Gleason Pattern Description 
1 Circumscribed nodule of closely packed but separate, uniform, rounded to 
oval, medium-sized acini that are larger than Gleason pattern 3 glands. 
2 Fairly circumscribed nodules; may have minimal infiltration of glands at the 
edge of the tumor nodule; 
Glands are more loosely arranged and not quite as uniform as Gleason 
pattern 1 glands. 
3 Discrete glandular units;  
Typically smaller glands than seen in Gleason pattern 1 or 2; 
Infiltrates in and amongst non-neoplastic prostate acini; 
Marked variation in size and shape; 
Smoothly circumscribed small cribriform nodules of tumor. 
4 Fused micro-acinar glands; 
Ill-defined glands with poorly formed glandular lumina; 
Large cribriform glands; 
Cribriform glands with an irregular border; 
Hypernephromatoid 
5 Essentially no glandular differentiation: composed of solid sheets, cords, or 
single cells; 
Comedocarcinoma with central necrosis surrounded by papillary, cribriform, 
or solid masses 
 
When evaluated by pathology, each prostate cancer biopsy specimen receives a primary 
and secondary Gleason pattern score of 1-5; added together, these numbers provide the total 
Gleason biopsy score of 2-10.  The first number represents the most common pattern in the 
specimen, while the second number represents the highest grade tumor in the specimen.   
For example, if a prostate biopsy specimen has 80% Gleason 3 prostate cancer and 20% 
Gleason 4 prostate cancer visible within the biopsy core on low-power magnification, the patient 
is diagnosed with Gleason 3 + 4 = 7 prostate cancer.     
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Table 1.3: Clinical staging of prostate cancer.
27
  
Clinical Stage Interpretation 
T1a Prostate cancer detected in ≤ 5% of resected tissue from a transurethral 
resection of the prostate; no palpable tumor on digital rectal exam 
(DRE) and no visible tumor on imaging 
T1b Prostate cancer detected in > 5% of resected tissue from a transurethral 
resection of the prostate; no palpable tumor on DRE and no visible 
tumor on imaging 
T1c Prostate cancer identified on prostate needle biopsy; no palpable tumor on 
DRE and no visible tumor on imaging 
T2a Palpable tumor in ≤ ½ of one side of the prostate on DRE and/or visible 
tumor ≤ ½ of one side of the prostate on imaging 
T2b Palpable tumor in > ½ of one side of the prostate on DRE and/or visible 
tumor in > ½ of one side of the prostate on imaging 
T2c Palpable tumor, or visible tumor on imaging, involving both lobes 
T3a Palpable tumor, or visible tumor on imaging, extends beyond the prostate 
capsule 
T3b Palpable tumor, or visible tumor on imaging, invades the seminal 
vesicle(s) 
T4 Tumor is fixed or invades adjacent structures (external sphincter, rectum, 
bladder, levator muscles, and/or pelvic wall) 
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Table 1.4: The University of California, San Francisco Cancer of the Prostate Risk Assessment 
(CAPRA) score.
28
 
Variable Range Points 
PSA (ng/mL) 2.0-6.0 
6.1-10.0 
10.1-20.0 
20.1-30.0 
> 30.0 
0 
1 
2 
3 
4 
Gleason score 
(primary/secondary) 
1-3/1-3 
1-3/4-5 
4-5/1-5 
0 
1 
3 
Clinical stage T1/T2
*
 
T3a
*
 
0 
1 
% positive biopsy cores <34% positive 
≥34% positive 
0 
1 
Age <50 years old 
≥50 years old 
0 
1 
*
Refer to Table 1.3. 
 
 The overall CAPRA score is determined by adding the points for each variable category.  
Men are then classified as low-, intermediate-, or high-risk as follows:
29
 
Risk Category CAPRA Score 
Low-risk 0-2 
Intermediate-risk 3-5 
High-risk 6-10 
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1.3          Appendix B: Study Selection Methodology 
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Figure 1.1: Overview of study selection methodology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PubMed
Terms: Prostatic Neoplasms OR prostatic neoplasms OR prostatic neoplasm OR Prostate Cancer OR Prostate Cancers 
OR Cancer of the Prostate OR Prostatic Cancers OR Prostatic Cancer AND active surveillance OR surveillance AND 
Gleason 7 OR Gleason Score 7 OR Gleason Score=7 OR Gleason Score<7 OR Gleason score 3+4
Inclusion Criteria: 
Men with Gleason 7 prostate cancer followed on 
active surveillance
3 relevant studies 
identified
3 studies reviewed in detail 
and included: Choo 2002,14 
Klotz 2005,15 van den Bergh 
200916
3 (Choo 2002,14 Klotz 2005,15 Klotz 201018) of 7 studies 
from same source population;
5 total studies for review: Cooperberg 2011,17 Klotz 
2010,18 Stattin 2010,19 van As 2008,20 van den Bergh 
200916
Subsequently Excluded upon Abstract Review: Oncologically irrelevant outcome data  
(n = 9), basic science of prostate cancer studies (n = 4), novel tests, treatments, and 
imaging studies (n = 36), studies with no data on men with Gleason 7 prostate cancer 
(n = 20), men not followed on active surveillance (n = 35)
Subsequently Excluded upon Methods/Results Review: Men not 
followed on true active surveillance (n=10)
4 additional studies identified from References: Cooperberg 2011,17
Klotz 2010,18 Stattin 2010,19 van As 200820
Exclusion Criteria: 
Prostate cancer review articles and expert opinion 
pieces (n = 8)
125 Studies
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Table 1.1: Description of included studies. 
Citation Study Population Data Source/ 
Measures 
Analysis Outcome(s)/Results Funding/ 
COI 
Cooperberg 
MR, et al. 
2011
17
  
Inclusion Criteria: Men 
with low (Gleason score 2-
6 AND CAPRA score 0-2) 
(Appendix A, Table 1.4) or 
intermediate-risk (Gleason 
score 7 OR CAPRA score 
3-5)  prostate cancer 
followed on active 
surveillance at UCSF;  
Minimum of 1 follow-up 
biopsy or PSA value 6-18 
months after diagnosis.  
 
Exclusion Criteria: 
CAPRA score 6-10, 
Gleason score 8-10, or cT3 
disease;  
<1 year follow-up.  
 
Demographics: Mean age 
at diagnosis: 62.8 ± 8.1 yrs;  
Intermediate risk group 
older (64.9 vs. 62.3 years; 
P<.01), higher PSA (10.9 
vs. 5.1 ng/mL; P<.01), and 
greater tumor involvement 
(20.4% vs. 15.3% positive 
biopsy cores; P < .01) 
compared to low-risk men. 
Source: 
Data from UCSF 
urologic 
oncology 
database. 
 
Measures: 
Patients followed 
with DRE and 
PSA every 3 
months, 
transrectal 
ultrasound every 
6-12 months, and 
follow-up 
prostate biopsy 
every 12-24 
months. 
 
PSA doubling 
time calculated 
as the time after 
the first 
measurement 
until the 
patient’s logPSA 
increased by a 
factor of 2. 
Demographic and 
disease 
characteristics 
between the low- 
and intermediate-
risk groups 
compared using 
chi-square or t-
tests. 
 
Kaplan-Meier 
analysis used to 
estimate 
progression-free 
survival. 
 
Poisson 
regression used to 
estimate the 
Gleason upgrade 
incidence rate per 
group. 
 
Cancer progression (upgrading on 
repeat biopsy): 
No difference: 111/313 (35%) low-
risk men vs. 19/63 (30%) 
intermediate-risk men upgraded on 
repeat biopsy; p=0.42. 
 
PSA doubling time:  
No difference: ≤ 2 years: 7% low-
risk vs. 5% intermediate-risk; 
p=0.52;  ≤ 3 years: 10% low-risk vs. 
11% intermediate-risk; p=0.80. 
 
Progression to active treatment 
(radical prostatectomy, radiation, or 
androgen deprivation therapy):  
No difference: 30% low-risk vs. 
35% intermediate-risk within 4 years 
of diagnosis; log-rank p=0.88. 
 
Subsequent nodal involvement or 
biochemical recurrence among men 
progressing to radical 
prostatectomy: None at 3 year 
follow-up among 58 low-risk and 16 
intermediate-risk men undergoing 
radical prostatectomy. 
Funding: 
UCSF  
Special 
Program of 
Research 
Excellence 
Grant; 
National 
Institutes 
of Health/ 
National 
Cancer 
Institute 
Grant. 
 
COI: 
Greene 
KL: stock 
ownership 
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Citation Study Population Data Source/ 
Measures 
Analysis Outcome(s)/Results Funding/ 
COI 
Klotz L, et 
al. 2010 
18
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion Criteria:  
Prostate cancer diagnosed  
within 12 months of study 
entry confirmed by central 
pathologic review; 
No previous 
treatment for prostate 
cancer; 
Men <70 years old with 
“favorable-risk” disease = 
Gleason ≤6, PSA ≤10 
ng/mL, and  clinical stage 
T1b-T2b; 
Men ≥70 years old with 
“favorable-risk” or 
intermediate risk disease = 
Gleason score ≤7 (3+4 
only) or PSA ≤15 ng/mL, 
and clinical stage T1b-T2b.  
 
Exclusion Criteria: 
Clinical stage ≥T2c, nodal 
or metastatic disease 
 
Demographics:  
Median age: 70.3 years; 
71% of patients “favorable 
risk” & 29% intermediate-
risk and either >70 years of 
age or with significant 
comorbidity.  
Source:  
Data from 
prospectively 
collected 
database  at 
Sunnybrook 
Health Sciences 
Centre, 
University of 
Toronto. 
 
Measures: 
PSA every 3 
months for 2 
years and then 
every 6 
months in stable 
patients; 
Confirmatory 
biopsy 6-12 
months after 
initial biopsy and 
then every 3-4 
years until age 
80.  
 
Patients re-
classified as 
higher risk and 
offered radical 
intervention for 
Kaplan-Meier 
survival analysis 
and log-rank test 
used to analyze 
overall survival, 
cause-specific 
survival, time to 
stopping active 
surveillance, and 
time to PSA 
failure. 
 
Cox proportional 
hazards 
regression 
analysis used to 
determine the 
hazard ratio 
between non–
prostate cancer 
mortality and 
prostate cancer 
mortality. 
 
Univariate 
logistic regression 
analysis used to 
determine the 
likelihood of 
being treated 
based upon PSA 
KM Analyses: 
Overall survival for entire cohort:  
353/450 (78.6%) at median follow-
up of 6.8 years; 10-year overall 
survival 68% (95% CI: 62-74%). 
 
Prostate cancer-specific survival for 
entire cohort: 
5-year cancer-specific survival: 
99.7%; 
10-year cancer-specific survival: 
97.2%.  
 
Time to PSA failure for entire 
cohort:  
Median 48 months in 117 patients 
treated with radical therapy after 
stopping active surveillance. 
 
Time to stopping active surveillance 
for entire cohort: 
At 2, 5, and 10 years, the likelihood 
that a patient remained on 
surveillance was 84, 72, and 62%, 
respectively. 
 
Cox Proportional Hazards analysis 
for the entire cohort: 
Hazard ratio for non-prostate cancer 
to prostate cancer mortality = 18.6 
(95% CI 7.6-45.7) at 10 years. 
 None 
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Klotz L, et 
al. 2010 
18
 
PSA doubling 
time <3 years, 
histologic 
upgrade on 
repeat prostate 
biopsy, or 
development of a 
palpable nodule. 
 
Biochemical 
recurrence 
defined as PSA 
>0.2 ng/mL for 
patients who 
underwent 
surgery and the 
PSA nadir + 2 
ng/mL for 
patients who 
received 
radiation. 
at baseline (>10 
ng/mL vs. ≤10 
ng/mL), stage at 
baseline (≥T2 vs. 
<2), and Gleason 
score at baseline 
(> 6 vs. ≤ 6). 
Univariate logistic regression 
analysis: 
Likelihood of proceeding for radical 
treatment related to Gleason score 
(odds ratio, 1.83, 95% CI 1.086-
3.097); P =.0233) and T stage 
≥T2a (odds ratio, 2.02; 95% CI 
1.305-3.133; P= .0016). 
 
 
Stattin P, et 
al. 2010
19
 
 
 
 
 
 
 
 
 
Inclusion Criteria:  
Men enrolled in the 
National Prostate Cancer 
Register of Sweden 
Follow-up Study diagnosed 
with clinical stage T1–2 
prostate cancer between 
1/1/97 and 12/31/2002 with 
a Gleason score ≤7, PSA 
<20 ng/mL, no lymph node 
Sources: 
National Prostate 
Cancer Registry, 
Swedish 
Population 
Register,   
Cause of Death 
Register, and 
review of death 
certificates. 
Distribution of 
patient 
characteristics by 
treatment group 
compared using 
chi square and t- 
tests. 
 
Pepe and Mori 
test used to 
Death from prostate cancer: 
Death was attributed to prostate 
cancer in 58/2021 (2.9%) patients in 
the surveillance group, 56/3339 
(1.7%) patients in the prostatectomy 
group, and 40/1429 (2.8%) patients 
in the radiation therapy group. 
 
Within the surveillance group, 14 
men with low-risk disease (1.3%) 
Funding: 
Swedish 
Research 
Council; 
Väster-
botten 
County 
Council; 
Swedish 
Cancer 
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Stattin P, et 
al. 2010
19
 
or bone metastases, and 
treated with surveillance 
(including active 
surveillance and watchful 
waiting) or curative intent 
(including radical 
prostatectomy or 
radiation).  
 
Exclusion Criteria: 
Primary hormonal 
treatment, Gleason 8-10 
tumors, missing PSA, 
stage, grade, or treatment 
data. 
 
Demographics:  
Mean age of surveillance 
group 64.7 ± 4.6 vs.  61.2 ± 
5.3 for prostatectomy 
group vs. 63.4 ± 4.9 years 
for the radiation group; 
In total, 2021 men in the 
surveillance group (93 with 
Gleason 7 disease), 3399 in 
the surgery group (601 
with Gleason 7 disease), 
and 1429 in the radiation 
group (280 with Gleason 7 
disease). 
 
Treatment data 
and surveillance 
termination 
information 
extracted from 
individual 
medical records 
by research 
nurses a median 
of 4 years after 
the date of 
diagnosis. 
 
Measures: 
No surveillance 
protocol; “active 
surveillance” 
group a mixture 
of men followed 
on surveillance 
and watchful 
waiting by 
individual 
physicians across 
Sweden. 
 
No defined 
triggers for 
transition to 
curative 
treatment. 
analyze the 
difference in the 
cumulative 
incidence of 
mortality between 
treatment groups. 
 
Cox proportional 
hazards model 
and competing- 
risks regression 
models used to 
determine relative 
risk of low- 
(clinical stage 
T1a-c, Gleason 
score ≤6 [or 
WHO grade I-II], 
and serum PSA 
<10 ng/mL) vs. 
intermediate-risk 
(clinical stage T2 
or Gleason score 
7 or serum PSA 
≥10 ng/mL) 
groups.   
died of prostate cancer, compared to 
44 (4.7%) men with intermediate 
risk disease. 
 
The calculated cumulated prostate 
cancer–specific mortality after 10 
years of follow-up was 3.6% (95% 
CI: 2.7- 4.8%) in the surveillance 
group vs. 2.4% in the prostatectomy 
group (95% CI: 1.8- 3.3%) vs. 3.3% 
(95%CI: 2.5-5.7%) in the radiation 
therapy group. 
 
Among those with low-risk disease, 
prostate cancer–specific mortality 
was 2.4% (95% CI: 1.2- 4.1%) in the 
surveillance group, 0.4% in the 
prostatectomy group (95% CI: 0.13-
0.97%) and 1.8% in the radiation 
therapy group (95% CI: 0.65- 4.0%). 
Among those in the intermediate-
risk category, prostate cancer–
specific mortality was 5.2% (95% 
CI: 3.7-6.9%) in the surveillance 
group, 3.4% (95% CI: 2.5- 4.7%) in 
the prostatectomy group, and 3.8% 
(95% CI: 2.6-5.4%) in the radiation 
therapy group. 
 
Among patients with intermediate 
risk disease, the risk of calculated 
Foundation 
 
COI:  
None 
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Analysis Outcome(s)/Results Funding/ 
COI 
After a median follow-up 
time of 4 years, 692/2021 
(34%) patients on 
surveillance received 
deferred treatment, which 
was radical prostatectomy 
for 277 men, radiation 
therapy for 207 men, and 
hormonal therapy for 208 
men. 
 
 
 
cumulative prostate cancer–specific 
death was significantly lower among 
patients in the prostatectomy group 
than among patients in the 
surveillance group (RR 0.49, 95% 
CI: 0.34-0.71). 
 
After multivariable adjustment, there 
was a lower risk of prostate cancer–
specific mortality among those in 
the prostatectomy group than among 
those in the surveillance group (RR 
0.49, 95% CI: 0.34-0.71), and 
among those in the radiation therapy 
group than among those in the 
surveillance group (RR 0.70, 95% 
CI: 0.45-1.09). 
 
Death from competing causes: 
413/2021 (20.4%) patients on active 
surveillance died in follow-up vs. 
286/3399 (8.4%) of the surgery 
patients vs. 196/1429 (13.7%) of the 
radiation therapy patients.   
 
The 10-year cumulative risk of 
dying of competing causes differed 
significantly by treatment received: 
19.2% (95% CI 17.2-21.3%) in the 
surveillance group vs. 8.5% (95% 
CI: 7.3-9.8%) in the prostatectomy 
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group, and 14.2% (95% CI: 11.7-
16.9%) in the radiation therapy 
group.  
 
Death from all causes: 
Calculated all-cause mortality at 10 
years of follow-up was 23.4% (95% 
CI: 21.3-25.8%) in the surveillance 
group, 11.3% (95% CI: 10.0-12.9%) 
in the radical prostatectomy group, 
and 18.3% (15.7-21.3%) in the 
radiation therapy group.  
van As NJ 
et al. 
2008
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Inclusion Criteria: 
Men ages 50-80 years old 
with clinical stage T1–T2a, 
N0–NX, M0–MX 
adenocarcinoma of the 
prostate with serum PSA 
<15 ng/ml, Gleason score 
≤7, primary Gleason grade 
≤ 3, and ≤50% positive 
biopsy cores.  All men 
were required to be of 
adequate health and fitness 
to undergo radical 
treatment.  
 
Exclusion Criteria:  
None specified. 
 
Demographics:  
Source:  
Data from 
prospectively 
collected 
database at 
Royal Marsden 
Hospital. 
 
Measures: 
Serum PSA 
monthly in year 
1, every 3 
months in year 2, 
and every 6 
months 
thereafter.  
DRE every 3 
months for 2 
years, then every 
Univariate and 
multivariate Cox 
regression 
analysis used to 
compare baseline 
clinical variables 
(initial PSA level, 
Gleason score, 
clinical T stage, 
free/total PSA 
ratio, PSA 
density, % 
positive 
cores, number of 
positive  cores, 
prostate volume, 
and 
maximum core 
involvement) and 
Time to radical treatment: 
At a median follow-up of 22 months 
(range: 1–56 months), 238/336 
patients (73%) remained on active 
surveillance, 65/336 (20%) 
underwent radical treatment, 16/336 
(5%) switched to watchful waiting 
because of increasing comorbidity, 
and 7/336 (2%) died of other causes.  
 
15/39 patients with Gleason 7 
disease proceeded for radical 
treatment, compared to 50/287 
patients with Gleason ≤3+3 disease.  
 
Median time to treatment was 15 
(range: 1–40) months. 
 
Among those undergoing treatment, 
Funding: 
Royal 
Marsden 
NHS Trust; 
NHS 
Executive; 
Institute of 
Cancer 
Research; 
Cancer 
Research 
UK Section 
of Radio-
therapy; 
Pelican 
Foundation 
 
COI: 
None 
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Median patient age 67 
(range 50-79) years, 
median initial PSA 6.4 
ng/ml (range 0.2-14.9), and 
17% median biopsy cores 
involvement (range 4-
50%). 
 
6 months 
thereafter. 
Repeat biopsy at 
18 -24 months 
and then every 2 
years. 
 
Indications for 
radical treatment 
included a PSA 
velocity >1 
ng/ml/yr, a  
Gleason score 
≥4+3, or >50% 
core involvement 
on repeat biopsy. 
 
Biochemical 
failure after 
radical treatment 
was defined as a 
PSA > 0.2 ng/ml 
after radical 
prostatectomy, 
or nadir + 2 after 
radiation 
therapy. 
time to radical 
treatment.  
4/65 experienced biochemical 
recurrence; no metastases or prostate 
cancer deaths have occurred. 
 
Univariate analysis showed that 
initial PSA level (HR 1.15, 95% CI: 
1.07-1.23; p< 0.001), free/total PSA 
ratio (HR 0.87, 95% CI: 0.83-0.92; 
p< 0.001), PSA density (HR 55.67, 
95% CI: 8.71-355.83; p<0.001), 
Gleason score (HR 2.43, 95% CI 
1.39-4.25; p=0.002); maximum 
percentage involvement of any core 
(HR 2.21, 95% CI: 1.34-3.65;p = 
0.002), % positive cores (HR 1.74, 
95% CI 1.06-2.86; p=0.03), clinical 
T stage (HR 1.86, 95% CI: 1.06-
3.25, p=0.03), number of positive 
cores (HR 1.64, 95% CI1.00-2.69; 
p=0.04), and prostate volume (HR 
0.98, 95% CI 0.97-0.99; p=0.04) 
were associated with time to radical 
treatment. 
 
On multivariate analysis, free/ 
total PSA ratio (HR 0.88, 95% CI: 
0.84-0.93; p< 0.001) and clinical T 
stage (HR 2.63, 95% CI 1.32-5.23; 
p=0.006) remained statistically 
significant determinants 
of time to radical treatment. 
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van den 
Bergh 
RCN, et al. 
2009
16
 
Inclusion criteria: Dutch, 
Swedish, and Finnish men 
50-75 years of age 
participating in the 
European Randomized 
Study of Screening for 
Prostate Cancer who had 
screen-detected prostate 
cancer with Gleason 7 
disease (3+4 or 4+3) on 
biopsy.  Patients self-
selected expectant 
management. 
 
Exclusion criteria: Men 
with positive lymph nodes 
or distant metastatic 
disease. 
  
Demographics:  
Mean age 69.5 (range: 
59.6-76.2) years; 44/50 
(88%) with Gleason 3+4 
disease; 6/50 (12%) with 
Gleason 4+3 disease; Mean 
PSA 5.7 ng/mL (range: 
2.5-15.9); Mean PSA 
density 0.18 (range: 0.05-
0.54); 40/50 (80%) cT1c; 
9/50 (18%) cT2; 32/50 
(64%) with 1 or 2 positive 
Source: 
Follow-up data 
collected from 
patient charts; 
mortality 
information 
obtained from 
National 
Registries. 
 
Measures: 
Men followed 
“expectantly” 
were followed 
with a mixture of 
active 
surveillance and 
watchful waiting 
by individual 
physicians at 
four centers 
participating the 
the European 
Randomized 
Study of 
Screening for 
Prostate Cancer 
in Sweden, 
Finland, and the 
Netherlands. 
 
Kaplan-Meier 
method and log-
rank test used to 
analyze prostate 
cancer-specific 
survival, overall 
survival and 
treatment-free 
survival.  
 
In a subgroup 
analysis, men 
with favorable 
risk Gleason 7 
disease (PSA 
≤10.0 ng/mL, 
cT1c/T2, PSA 
density <0.2 
ng/mL/mL, and 
two or fewer 
positive biopsy 
cores) were 
compared to men 
with less 
favorable risk 
Gleason 7 disease 
using the Kaplan-
Meier method and 
log-rank test. 
Prostate cancer-specific 
survival: 
6-year cancer-specific 
survival: 100% 
 
Overall survival: 
6-year overall survival: 
68%; 
 
Treatment-free survival: 
6-year treatment-free 
survival: 59% 
 
Median time to deferred 
active therapy was 1.4 
(IQR 0.7-3.0) years. 
 
Subgroup Analysis: Men 
with less favorable risk 
Gleason 7 disease (29/50 
men) were more likely to 
transition to deferred 
active therapy than were 
men with favorable risk 
Gleason 7 disease (log- 
rank p<0.001). 
 
Funding: 
Beckman Coulter 
Ltd.; Dutch Cancer 
Society; Netherlands 
Organization for 
Health Research and 
Development; 6
th
 
Framework Program 
of the EU; Europe 
against Cancer; 
Swedish Cancer 
Society; Schering 
Plough;  Abbot; 
Gunvor and Ivan 
Svensson’s 
Foundation; Af 
Jochnick’s 
Foundation; 
Academy of Finland; 
Cancer Society of 
Finland; Sigrid 
Juselius Foundation; 
Competitive 
Research Funding of 
the Pirkanmaa 
Hospital District;  
Helsingin Sanomat 
Centenarian Fund; 
Hybritech Corp; 
Foundation for 
Finnish Culture 
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cores; 10/50 (20%) with 3 
or 4 positive cores; Mean 
6.7 total biopsy cores 
(range 5-12).  
No defined 
triggers for 
transition to 
curative 
treatment. 
 
COI: 
Schröder FH: Ferring 
Ltd; 
Glaxo-Smith Kline; 
Bayer; Schering; 
Cougar 
Biotechnology; 
Genprobe 
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Table 1.2: Quality assessment of included studies. 
Author Study 
Design 
Points Sample 
Size 
Points Primary 
Outcome(s) 
Points Follow-up Points Bias Points Total 
Cooperberg 
MR, et al. 
2011
17
 
Single 
institution  
prospective 
cohort with 
control 
group 
3 Total: 466 
men 
Subset of 
Gleason 7 
men: 29 
1 - Gleason 
score 
progression 
on repeat 
biopsy 
- PSA kinetics 
- Progression 
to active 
treatment 
1 Mean: 51 
months 
(range: 
14-140 
months) 
months for 
intermediate 
risk men 
2 ++ 2 9 
Klotz L, et 
al. 2010
18
 
Single 
institution 
prospective 
cohort 
2 Total: 450 
men 
Subset of 
Gleason 7 
men: 72 
2 - Overall 
survival 
- Prostate-
cancer 
specific 
survival 
3 Median: 6.8 
years 
(range: 
1-13 years) 
2 ++ 2 10 
Stattin P, et 
al. 2010
19
 
National 
population-
based 
retro-
spective 
cohort 
2 Total: 6849 
men; 
Subset of 
Gleason 7 
men: 93 
2 - Prostate-
cancer 
specific 
mortality 
- Risk of death 
from 
competing 
causes 
- Death from 
all causes 
3 Median: 8.2 
years (IQR 
7.1-9.7 
years) 
3 ++ 3 13 
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Author Study 
Design 
Points Sample 
Size 
Points Outcome(s) Points Follow-up Points Bias Points Total 
van As NJ, 
et al.
20
 
Single 
institution 
prospective 
cohort 
2 Total: 326 
men 
Subset of 
Gleason 7 
men: 39 
1 - Time to 
radical 
treatment 
1 Median: 22 
months 
(range 
1-56 
months) 
1 ++ 2 7 
van den 
Bergh 
RCN, et al. 
2009
16
 
Case series 1 Total: 50 
men, all 
with 
Gleason 7 
prostate 
cancer 
1 - Cancer-
specific 
survival 
- Overall 
survival 
- Treatment-
free survival 
3 Mean: 3.4 
years 
(range: 
0.0-11.6 
years) 
1 +++ 1 6 
 
The above table displays the quality rating for each study included in this review.  Each category was graded on scales of 1 
(lowest) to 3 (highest).  Combining scores for study design, sample size, outcome measures, length of follow-up, and risk of bias, the 
quality score for each study could range from 5 (lowest quality) to 15 (highest quality). 
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ABSTRACT 
Purpose 
To examine if there is a subset of men with Gleason 7 (3+4) prostate cancer who may be potential 
candidates for active surveillance. 
Materials and Methods 
We used the SEARCH database to identify 870 men undergoing radical prostatectomy from 2001-13 
with >8 biopsy cores and complete clinical information. We compared characteristics of men who 
fulfilled low-risk disease criteria (clinical stage T1c/T2a; biopsy Gleason ≤6; PSA ≤10 ng/mL) with 
the exception of biopsy Gleason 7 (3+4) vs. men who met all 3 low-risk criteria.  Logistic regression 
was used to test the association between biopsy Gleason and pathological features. Biochemical 
recurrence was examined using Cox hazards analysis. To examine whether there was a subset of men 
with low-volume Gleason 7 with comparable outcomes to low-risk men, we repeated all analyses 
limiting the percentage positive cores to ≤33% and positive cores to ≤4, ≤3, or ≤2.  
Results 
Gleason 7 low-risk men had increased risk of pathological Gleason ≥4+3 (p<0.001), positive margins 
(p=0.070), extracapsular extension (p<0.001), seminal vesicle invasion (p=0.005), and higher 
biochemical recurrence (HR 1.65, p=0.006). Using increasingly strict definitions of low-volume 
disease, at ≤3 positive cores there was no difference in adverse pathology between groups (all p>0.1), 
except higher pathological Gleason score (p<0.001). Biochemical recurrence was similar in men with 
Gleason 6 or Gleason 7 (3+4) (HR 1.39; p=0.254).   
Conclusion 
Among men with PSA≤10 ng/mL and clinical stage T1c/T2a, those with Gleason 7 (3+4) in ≤3 total 
positive cores have similar rates of adverse pathology and biochemical recurrence as men with 
Gleason ≤6. 
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INTRODUCTION 
Active surveillance is an attractive option to avoid overtreatment for men with low-risk 
disease typically defined as Gleason score ≤6, PSA ≤10 ng/mL, clinical stage ≤T2a,30 low 
disease volume on biopsy (limited by percentage or total number of positive cores),31-34 and low 
PSA density.35, 36  Among men meeting these criteria, prostate cancer specific mortality is low 
and radical treatment is avoided.9  Limited data exist on the inclusion of men with intermediate-
risk prostate cancer, including Gleason 7, into active surveillance protocols.  In the University of 
Toronto’s active surveillance cohort, 72 (17%) men had Gleason 3+4.  Relative to men with 
Gleason score ≤6, those with Gleason 3+4 were 1.8 times more likely to undergo radical 
treatment.30  Conversely, Cooperberg et al. reported that among 90 men with intermediate-risk 
disease undergoing active surveillance at UCSF, there was no difference in progression-free 
survival or the proportion of men undergoing treatment within a four year period versus men 
with low-risk disease.37  Most recently, Musunuru et al. presented an abstract reporting lower 
overall survival and cause-specific survival in 237 patients with PSA>10ng/mL or Gleason score 
7 or clinical stage T2b/2c followed on active surveillance at a single institution.38     
As Gleason 7 is now the most common score on biopsy,10 we examined if there was a 
subset of men with Gleason 7 (3+4) who would be reasonable candidates for active surveillance.  
We hypothesized that by defining PSA, clinical stage, and volume criteria on biopsy, we could 
identify a group of men with Gleason 7 (3+4) who would be candidates for active surveillance, 
thereby further reducing prostate cancer overtreatment. 
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MATERIALS AND METHODS 
Study population 
After obtaining IRB approval, data from patients at Veterans Administration (VA) 
Medical Centers (Palo Alto, CA; West Los Angeles, CA; San Diego, CA; Durham, NC; 
Augusta, GA) were combined into the Shared Equal Access Regional Cancer Hospital Database 
(SEARCH).  As few men treated prior to 2001 had adequate prostate sampling (defined as >8 
cores), we limited analyses to men treated in 2001 or later biopsied per physician standard 
practice (n=2,810). We excluded men with missing data on race (n=3), PSA (n=16), biopsy 
Gleason (n=24), pathological Gleason (n=15), clinical stage (n=170), number of cores taken 
(n=282), number of positive cores (n=39), positive margins (n=14), extracapsular extension 
(n=14), seminal vesicle invasion (n=6), and surgical technique (n=10). Of the remaining 2,217 
men, 870 met our study criteria of PSA ≤10 ng/mL, biopsy Gleason ≤7 (3+4), clinical stage T1c 
or T2a, and >8 cores on biopsy.  In a subset analysis, we further excluded men with missing PSA 
density data (n=132).  In this subset, 738 men met study inclusion criteria. 
We compared men who fulfilled the criteria of AUA low-risk disease (clinical stage 
T1c/T2a, biopsy Gleason ≤6 and PSA ≤10 ng/mL)6-8 with the exception of biopsy Gleason 7 
(3+4) (henceforth “Gleason 7 low-risk”) versus men who met all 3 criteria for AUA low-risk.  
We used this definition of low-risk disease for comparison because active surveillance is a 
recommended treatment option for men meeting these criteria in the National Comprehensive 
Cancer Network Guidelines.8    
Statistical analysis 
Differences in demographic and clinicopathological features between the Gleason 7 low-
risk and AUA low-risk group were examined using t-tests for normally distributed continuous 
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variables, Wilcoxon rank-sum tests for non-normally distributed continuous variables, chi-square 
tests for categorical variables, and Fisher’s exact test for categorical variables with any cell count 
≤5. 
Crude and adjusted logistic regression models were used to test the association between 
risk group (Gleason 7 low-risk vs. AUA low-risk) and pathological features (pathological 
Gleason score [≤6 vs. ≥4+3], positive margins, extracapsular extension, and seminal vesicle 
invasion).  Models were adjusted for age at surgery (continuous), surgery year (continuous), race 
(white vs. black vs. other), number of biopsy cores (continuous), surgical center, surgical 
technique, clinical stage (T1c vs. T2a), and PSA (log-transformed, continuous). 
On average, men were evaluated every 3 months in the first year post-operatively, every 
6 months in years 2-3, and annually thereafter.  Biochemical recurrence was defined as a single 
PSA >0.2 ng/mL, two consecutive PSAs of 0.2 ng/mL, or secondary treatment for elevated PSA 
in the post-operative period.  Hazard ratios (HR) for biochemical recurrence between Gleason 7 
low-risk and D’Amico low-risk were analyzed using Cox proportional hazards analysis, 
adjusting for age at surgery (continuous), surgery year (continuous), race (white vs. black vs. 
other), surgical center, surgical technique, clinical stage (T1c vs. T2a), PSA (log-transformed, 
continuous), and biopsy cores taken (continuous).  Biochemical recurrence was examined using 
the Kaplan-Meier method and comparisons between the groups were performed using the log-
rank test. 
 All analyses were repeated with matching of the percentage or number of positive biopsy 
cores between the Gleason 7 low-risk and the D’Amico low-risk group, including positive cores 
≤33%, ≤4 positive cores, ≤3 positive cores, and ≤2 positive cores.  
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 In a subset analysis including men with PSA density data, all analyses were repeated 
limiting the PSA density threshold between the Gleason 7 low-risk and the D’Amico low-risk 
group at ≤0.30, ≤0.25, ≤0.20, ≤0.15, and ≤0.10 ng/mL/g. 
 Statistical analyses were performed using Stata 13.1 (Stata, Corp., College Station, TX, 
USA). Statistical significance was two-sided with p<0.05. 
RESULTS 
D’Amico Low-Risk Patients vs. Gleason 7 Low-Risk Patients   
Baseline characteristics of the 870 men who met inclusion criteria are shown in Table 
2.1. Among them, 495 (57%) had D’Amico low-risk and 375 (43%) had Gleason 7 low-risk.  
The Gleason 7 low-risk group had a more recent median surgery year versus the D’Amico low-
risk group (2011 vs. 2008; p<0.001), were more likely to have a robotic prostatectomy (47% vs. 
32%; p<0.001), and undergo a pelvic lymph node dissection (PLND) (67% vs. 38%; p<0.001).  
Among men whose cancer did not recur, median post-operative follow-up was significantly 
shorter in the Gleason 7 low-risk group (22.0 vs. 48.8 months; p<0.001).  As expected, Gleason 
7 low-risk men had higher pre-surgery PSA (5.6 vs. 5.3 ng/mL; p=0.011), more positive cores (4 
vs. 2; p<0.001), and higher rates of extracapsular extension (15 vs. 7%; p<0.001), seminal 
vesicle invasion (8 vs. 2%, p<0.001), and positive lymph nodes (2 vs. <1%; p=0.024) versus 
D’Amico low-risk men.  Consistent with Gleason grading on prostate biopsy, Gleason 7 low-risk 
men were more likely to have higher pathological grade versus D’Amico low-risk men (13 vs. 
46% Gleason 2-6; 62 vs. 44% Gleason 3+4; 24 vs. 10% Gleason ≥4+3; p<0.001). There were no 
significant differences in patient age, race, or clinical stage. 
The Gleason 7 low-risk group had higher pathological Gleason scores, more 
extracapsular extension, and more seminal vesicle invasion, in both crude and adjusted models 
(all p<0.01) (Table 2.2).  The risk of positive margins was not significantly different between 
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groups.  Gleason 7 low-risk men had higher rates of biochemical recurrence than D’Amico low-
risk men (log-rank, p=0.003; Figure 2.1a). 
In order to identify if there were subsets of men with Gleason 7 low-risk disease with 
outcomes similar to D’Amico low-risk men, we assessed the effect of limiting the analysis to 
men with low-volume disease, using varying definitions of “low-volume”. As the definition of 
low-volume became increasingly strict (i.e. fewer cores positive), the HR for biochemical 
recurrence between the Gleason 7 low-risk group and the D’Amico low-risk group became 
increasingly smaller (i.e. closer to 1) (Table 2.3).  At ≤3 positive cores, the difference in 
biochemical recurrence risk between the Gleason 7 low-risk and the D’Amico low-risk group 
lost statistical significance (HR 1.39; p=0.254).     
Analysis of Gleason 7 Low-Risk Patients vs. D’Amico Low-Risk Patients with ≤3 Total Positive 
Cores  
As biochemical recurrence risk was comparable between the Gleason 7 low-risk and 
D’Amico low-risk group when restricted to men with ≤3 total positive cores, we repeated the 
analysis comparing baseline characteristics (Table 2.4), risk of adverse pathology (Table 2.5), 
and biochemical recurrence risk (Figure 2.1b) between these groups. There were 334 men (68%) 
with D’Amico low-risk disease and ≤3 positive biopsy cores and 157 men (32%) with Gleason 7 
low-risk disease and ≤3 positive biopsy cores.  Consistent with the larger cohort of men 
previously reviewed, the Gleason 7  low-risk group with ≤3 total positive cores had a more 
recent median year of surgery than the D’Amico low-risk group (2010 vs. 2007; p <0.001), were 
more likely to undergo a robotic prostatectomy (47% vs. 27%; p<0.001), and PLND (64% vs. 
35%; p<0.001).  Median post-operative follow-up was significantly shorter in the Gleason 7 low-
risk group compared to the D’Amico low-risk group (22.9 vs. 51.4 months; p<0.001).  While 
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limiting the number of positive cores to ≤3, men in the Gleason 7 low-risk group were more 
likely to have 2 or 3 positive cores versus the D’Amico low-risk group (p<0.001).  Consistent 
with biopsy Gleason grading, pathological Gleason scores were higher in the Gleason 7 low-risk 
group compared to the D’Amico low-risk group (17 vs. 53% Gleason 2-6; 61 vs. 38% Gleason 
3+4; 22 vs. 9% Gleason ≥4+3; p<0.001).  There were no significant differences in patient age, 
race, PSA at diagnosis, clinical stage, or rates of extracapsular extension, seminal vesicle 
invasion, positive margins, or positive nodes between groups.      
The likelihood of the Gleason 7 low-risk group having a pathological Gleason score ≥4+3 
remained statistically greater than the D’Amico low-risk group (p=0.005) (Table 2.5).  However, 
the risk of positive margins, extracapsular extension, and seminal vesicle invasion were similar 
between the Gleason 7 low-risk and the D’Amico low-risk group.  There was no significant 
difference in biochemical recurrence risk between the two groups (log-rank, p=0.331; Figure 
2.1b).       
Supplementary Table 2.1 shows the stratification of D’Amico low-risk and biopsy 
Gleason 3+4 low-risk men by year of surgery.  Over time, the number of Gleason 7 low-risk men 
undergoing surgery is increasing.    
Subset Analysis: D’Amico Low-Risk Patients vs. Gleason 7 Low-Risk Patients with PSA Density 
Data 
 An alternative means to select “low-risk” men with Gleason 7 is to limit to men with low 
PSA density. To address this, we evaluated progressively lower PSA density thresholds, and 
found that men with Gleason 7 low-risk had significantly higher biochemical recurrence risk 
than the D’Amico low-risk group, until the PSA density was ≤0.10 ng/mL/g, when results were 
similar (HR 1.44; p=0.451) (Supplementary Table 2.2).      
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DISCUSSION  
 Limited and conflicting data on the outcomes of men with intermediate-risk prostate 
cancer on active surveillance exist.  As Gleason 7 disease is now the most common score on 
biopsy,10 we examined if a subset of Gleason 7 prostate cancer patients had similar outcomes to 
low-risk patients and thus could be reasonable potential active surveillance candidates.  Using 
the SEARCH database of men undergoing radical prostatectomy, we compared men who 
fulfilled the D’Amico low-risk disease criteria versus men with Gleason 7 low-risk prostate 
cancer, but who otherwise fulfilled the D’Amico low-risk disease criteria.  We explored 
associations between risk group, pathological features, and biochemical recurrence, with 
matching of PSA density (subset analysis) and the percentage or number of positive cores 
between the Gleason 7 low-risk and the D’Amico low-risk group.  We found that among men 
with PSA≤10 ng/mL and clinical stage T1c/T2a, those with Gleason 7 (3+4) prostate cancer and 
a PSA density ≤0.10 ng/mL/g had similar rates of adverse pathology and biochemical recurrence 
as men with Gleason ≤6.  The number of men meeting this PSA density threshold was ~2% of 
SEARCH over the study time period. We found that among men with PSA≤10 ng/mL and 
clinical stage T1c/T2a, those with Gleason 7 (3+4) prostate cancer in ≤3 positive cores had 
similar rates of adverse pathology and biochemical recurrence as men with Gleason ≤6.  The 
number of men meeting this cutoff was ~6% of SEARCH.  The inclusion of these men on active 
surveillance protocols would reduce prostate cancer overtreatment, and additional study is 
warranted to assess the safety of this approach. 
 Previous studies established higher rates of biochemical recurrence, metastases, and 
cancer specific death39-41 in men with Gleason 7 versus those with Gleason ≤6.  The 
heterogeneity of prostate cancer outcomes in men with Gleason 7 disease is recognized to 
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strongly correlate with primary Gleason grade (3 vs. 4).30, 42  While active surveillance for low-
risk disease has made progressive in-roads to mitigate prostate cancer overtreatment, a decrease 
in non-curative initial management among men with intermediate-risk prostate cancer has been 
observed in U.S. population level datasets.3   
Our interest in the possible expansion of active surveillance to a defined population of 
men with intermediate-risk prostate cancer is shared.  In a European multi-institutional dataset, 
Gandaglia et al. reported no significant biochemical recurrence difference between 564 men with 
Gleason 3+4 organ-confined disease and 926 men with Gleason 3+3 organ-confined disease who 
preoperatively met PRIAS criteria for active surveillance.43  In a single-institution radical 
prostatectomy dataset, Kwon et al. identified 217 men with Gleason 3+4 disease who otherwise 
fulfilled at least one common active surveillance protocol criteria (Hopkins,35 MSKCC,32 
PRIAS,44 Miami,33 UCSF,45 or Toronto30).  They found the rate of pathologically aggressive 
disease would not significantly increase with expansion of active surveillance criteria to include 
Gleason 3+4 under most contemporary protocols.46   
In a retrospective review of 2,323 men who underwent radical prostatectomy for Gleason 
3+4 at six European institutions, Ploussard et al. determined that 46% had unfavorable disease at 
final pathology.  However, by narrowing their selection criteria to men with PSA ≤10 ng/mL, 
PSA density ≤0.15 ng/mL/g, clinical stage T1c, and ≤2 positive cores, the rate of adverse disease 
was 19%, leading the authors to conclude that expanding active surveillance to these men may be 
acceptable provided strict adherence to selection criteria.47   
Similar to Ploussard’s analysis, we explored a PSA density of ≤0.15 ng/mL/g and ≤2 
positive cores as cut-points.  While pathologic outcomes and biochemical recurrence were 
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similar between Gleason 7 low-risk and D’Amico low-risk group with ≤2 positive cores in our 
cohort, we found a threshold PSA density of ≤0.10 ng/mL/g was needed to achieve similar 
outcomes between the groups. In SEARCH, <4% of men had Gleason 7 low-risk disease and ≤2 
positive cores on biopsy.  However, by increasing our cut-point to ≤3 total positive cores, we 
nearly doubled the number of men included as “low-risk” while still maintaining no significant 
difference in pathological outcomes or biochemical recurrence.  With the objective of 
minimizing overtreatment, we elected to proceed with the less stringent criterion of ≤3 total 
positive cores.  
Including men with Gleason 7 (3+4), PSA ≤10 ng/mL, clinical stage T1c/T2a, and ≤3 
total positive cores would considerably expand the population eligible for active surveillance.  In 
our study, among men with Gleason 7 low-risk disease, 42% had ≤3 total positive cores on 
biopsy.  Men meeting our Gleason 7 low-risk disease criteria with ≤3 total positive cores 
comprised 10+% of the entire SEARCH population over the past two years.   
Our study has the inherent limitations of all retrospective analyses.  While our dataset 
included men from five VA centers, central pathology review was not completed.  Changes in 
Gleason grading during our study period may limit study validity.  Pathologic findings serve as 
intermediate endpoints for aggressive disease and may not predict disease-specific or overall 
survival; overall survival was not included as few deaths occurred in the cohort.  Year of surgery 
and follow-up length between our D’Amico low-risk and Gleason 7 low-risk groups were 
significantly different and introduce possible bias.  As SEARCH is a radical prostatectomy 
database, an inherent selection bias exists.  Finally, as all men with Gleason 3+4 low-risk in our 
dataset underwent radical prostatectomy, it is unknown if their outcomes with intervention 
reflect the natural history of Gleason 3+4 low-risk monitored on active surveillance.  
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CONCLUSION  
Among men with PSA≤10 ng/mL and clinical stage T1c/T2a, those with Gleason 7 (3+4) 
prostate cancer in ≤3 total positive cores have similar rates of adverse pathology and biochemical 
recurrence as men with Gleason ≤6 disease. This finding, if confirmed in additional cohorts, may 
expand active surveillance protocol inclusion criteria to further reduce prostate cancer 
overtreatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXTERNAL FUNDING  
 
None 
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2.2          Manuscript Tables and Figures 
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Table 2.1: Baseline characteristics between D’Amico low-risk* and biopsy Gleason 3+4 low-risk 
patients 
 
D’Amico low-risk 
N=495 (57%) 
Gleason 7 low-risk  
N=375 (43%) 
p-value 
Age, mean ± SD 60.6 ± 5.8 61.4 ± 6.2 0.070† 
Year of surgery 2008 (2005, 2010) 2011 (2007, 2012) <0.001‡ 
Race, n (%)   0.100§ 
White 252 (51) 164 (44)  
Black 212 (43) 181 (48)  
Other 31 (6) 30 (8)  
PSA (ng/ml) 5.3 (4.3, 7.0) 5.6 (4.6, 7.0) 0.011‡ 
Clinical Stage (%)   0.333§ 
T1c 405 (82) 297 (79)  
T2a 90 (18) 78 (21)  
# Cores 12 (10, 12) 12 (11, 12) <0.001‡ 
Positive cores 2 (1, 4) 4 (3, 6) <0.001‡ 
Follow-up (months) 48.8 (23.4, 84.5) 22.0 (8.1, 50.3) <0.001‡ 
Surgical Technique, n (%)  <0.001§ 
Open RRP 286 (58) 172 (46) 
Perineal prostatectomy 32 (6) 17 (5) 
Laparoscopic prostatectomy 21 (4) 9 (2) 
RARP 156 (32) 177 (47) 
Pathological Gleason score, n (%)  <0.001§ 
2 – 6 229 (46) 50 (13)  
3+4 216 (44) 234 (62)  
4+3, 8 – 10 50 (10) 91 (24)  
Extracapsular extension, n (%) 35 (7) 56 (15) <0.001§ 
Seminal vesicle invasion, n (%) 10 (2) 30 (8) <0.001§ 
Positive margins, n (%) 178 (36) 157 (42) 0.074§ 
PLND performed, n (%) 186 (38) 253 (67) <0.001§ 
Positive lymph nodes, n (%) 1 (<1) 7 (2) 0.013# 
 
Cells display median (25th percentile, 75th percentile) unless otherwise noted 
P-value calculated using † t-test, ‡ rank sum test, § chi-square test, or # Fisher’s exact test  
 
*D’Amico low-risk patients had PSA≤10, clinical stage T1c-T2a, biopsy Gleason ≤6, and more 
than 8 cores taken on biopsy.  
Biopsy Gleason 3+4 low-risk patients had PSA ≤10, clinical stage T1c-T2a, biopsy Gleason 3+4, 
and more than 8 cores taken on biopsy. 
 
RRP = Radical retropubic prostatectomy 
RARP = Robotic assisted radical prostatectomy 
PLND = Pelvic lymph node dissection 
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Table 2.2: Odds ratios for risk group predicting pathological features between D’Amico low-risk 
and biopsy Gleason 3+4 low-risk patients. 
 
 OR 95% CI p –value 
Pathological Gleason ≥ 4 + 3    
Crude 2.85 1.96 – 4.15 < 0.001 
Adjusted* 2.22 1.47 – 3.36 < 0.001 
Positive margins    
Crude 1.28 0.97 – 1.69 0.076 
Adjusted* 1.32 0.98 – 1.79 0.070 
Extracapsular extension    
Crude 2.31 1.48 – 3.60 < 0.001 
Adjusted* 2.60 1.60 – 4.23 < 0.001 
Seminal vesicle invasion    
Crude 4.22 2.03 – 8.74 < 0.001 
Adjusted* 3.10 1.42 – 6.78 0.005 
 
* Adjusted for age, year, race, surgical center, surgical technique, clinical stage, number of 
biopsy cores taken, and PSA 
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Table 2.3: Hazard ratios for risk of biochemical recurrence for biopsy Gleason 3+4 low risk 
group relative to D’Amico low-risk group* stratified by number of positive biopsy cores. 
 
Entry Criteria Number of 
D’Amico low 
risk patients 
Number of 
Gleason 7 low 
risk patients 
HR 95% CI p-value 
All 495 375 1.65 1.15 – 2.36 0.006 
<33% positive cores 376 202 1.86 1.16 – 3.00 0.011 
≤ 4 positive cores  394 208 1.80 1.14 – 2.84 0.012 
≤ 3 positive cores 334 157 1.39 0.79 – 2.45 0.254 
≤ 2 positive cores 248 88 1.29 0.59 – 2.81 0.519 
 
* D’Amico low-risk patients had PSA≤10, clinical stage T1c-T2a, biopsy Gleason ≤6, and more 
than 8 cores taken on biopsy.  
Biopsy Gleason 3+4 low-risk patients had PSA ≤10, clinical stage T1c-T2a, biopsy Gleason 3+4, 
and more than 8 cores taken on biopsy. 
  
52 
 
Table 2.4: Baseline characteristics between D’Amico low-risk* and biopsy Gleason 3+4 low-risk 
patients with ≤3 total positive biopsy cores.  
 
D’Amico low-risk 
N=334 (68%) 
Gleason 7 low-risk  
N=157 (32%) 
p-value 
Age, mean ± SD 61.0 ± 5.7 62.2 ± 6.1 0.037† 
Year of surgery 2007 (2004, 2010) 2010 (2007, 2012) <0.001‡ 
Race, n (%)   0.069§ 
White 174 (52) 67 (43)  
Black 142 (42) 75 (48)  
Other 18 (5) 15 (10)  
PSA (ng/ml) 5.3 (4.3, 6.8) 5.5 (4.5, 6.6) 0.285‡ 
Clinical Stage (%)   0.582§ 
T1c 279 (84) 128 (82)  
T2a 55 (16) 29 (18)  
# Cores 12 (10, 12) 12 (11, 12) 0.005‡ 
Positive cores 2 (1, 3) 2 (2, 3) <0.001‡ 
Follow-up (months) 51.4 (27.4, 85.6) 22.9 (11.7, 51.7) <0.001‡ 
Surgical Technique, n (%)  <0.001§ 
Open RRP 201 (60) 76 (48) 
Perineal prostatectomy 25 (7) 6 (4) 
Laparoscopic prostatectomy 17 (5) 2 (1) 
RARP 91 (27) 73 (47) 
Pathological Gleason score, n (%)  <0.001§ 
2 – 6 177 (53) 26 (17)  
3+4 127 (38) 96 (61)  
4+3, 8 – 10 30 (9) 35 (22)  
Extracapsular extension, n (%) 21 (6) 12 (8) 0.576§ 
Seminal vesicle invasion, n (%) 6 (2) 6 (4) 0.175§ 
Positive margins, n (%) 102 (31) 57 (36) 0.203§ 
PLND performed, n (%) 116 (35) 100 (64) <0.001§ 
Positive lymph nodes, n (%) 1 (<1) 1 (1) 0.538# 
 
Cells display median (25th percentile, 75th percentile) unless otherwise noted 
P-value calculated using † t-test, ‡ rank sum test, § chi-square test, or # Fisher’s exact test  
 
*D’Amico low-risk patients had PSA≤10, clinical stage T1c-T2a, biopsy Gleason ≤6, more than 
8 cores taken on biopsy, and ≤ 3 positive biopsy cores.  
Biopsy Gleason 3+4 low-risk patients had PSA ≤10, clinical stage T1c-T2a, biopsy Gleason 3+4, 
more than 8 cores taken on biopsy, and ≤ 3 positive biopsy cores.   
 
RRP = Radical retropubic prostatectomy 
RARP = Robotic assisted radical prostatectomy 
PLND = Pelvic lymph node dissection  
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Table 2.5: Odds ratios for risk group predicting pathological features between D’Amico low-risk 
and biopsy Gleason 3+4 low-risk patients with ≤3 total positive biopsy cores.  
 
 OR 95% CI p –value 
Pathological Gleason ≥ 4 + 3    
Crude 2.91 1.71 – 4.94 < 0.001 
Adjusted* 2.36 1.30 – 4.29 0.005 
Positive margins    
Crude 1.30 0.87 – 1.93 0.203 
Adjusted* 1.55 0.99 – 2.42 0.057 
Extracapsular extension    
Crude 1.23 0.59 – 2.58 0.576 
Adjusted* 1.48 0.65 – 3.38 0.347 
Seminal vesicle invasion    
Crude 2.17 0.69 – 6.85 0.185 
Adjusted* 2.18 0.60 – 7.98 0.238 
 
* Adjusted for age, year, race, surgical center, surgical technique, clinical stage, number of 
biopsy cores taken, and PSA 
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Figure 2.1:  
a. Kaplan-Meier curves comparing biochemical recurrence-free survival for D’Amico low-
risk and Gleason 7 (3+4) low-risk prostate cancer. 
 
 
b. Kaplan-Meier curves comparing biochemical recurrence-free survival for D’Amico low-
risk and Gleason 7 (3+4) low-risk prostate cancer ≤3 total positive biopsy cores. 
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SUPPLEMENTARY MATERIAL:  
Table 2.1:  
a. Stratification of D’Amico low-risk* and biopsy Gleason 3+4 low-risk patients by year of 
surgery. 
Year of Surgery SEARCH database 
N = 2810 
D’Amico low-risk 
N=495 
Gleason 7 low-risk  
N=375 
2001, n (% of SEARCH) 165 19 (12) 8 (5) 
2002 184 31 (17) 6 (3) 
2003 211 38 (18) 7 (3) 
2004 222 34 (15) 20 (9) 
2005 200 40 (20) 23 (12) 
2006 204 39 (19) 22 (11) 
2007 196 34 (17) 18 (9) 
2008 194 48 (25) 16 (8) 
2009 230 48 (21) 30 (13) 
2010 220 41 (19) 35 (16) 
2011 254 52 (20) 42 (17) 
2012 290 46 (16) 78 (27) 
2013 240 25 (10) 70 (29) 
 
b. Stratification of D’Amico low-risk* and biopsy Gleason 3+4 low-risk patients with ≤3 
total positive biopsy cores by year of surgery. 
Year of Surgery SEARCH database 
N = 2810 
D’Amico low-risk 
N=334  
Gleason 7 low-risk  
N=157 
2001, n (% of SEARCH) 165 15 (9) 4 (2) 
2002 184 24 (13) 3 (2) 
2003 211 26 (12) 4 (2) 
2004 222 25 (11) 9 (4) 
2005 200 26 (13) 7 (4) 
2006 204 32 (16) 10 (5) 
2007 196 22 (11) 3 (2) 
2008 194 29 (15) 7 (4) 
2009 230 36 (5) 17 (7) 
2010 220 29 (13) 15 (7) 
2011 254 33 (13) 17 (7) 
2012 290 21 (7) 38 (13) 
2013 240 16 (7) 23 (10) 
* D’Amico low-risk patients had PSA≤10, clinical stage T1c-T2a, biopsy Gleason ≤6, and more 
than 8 cores taken on biopsy.  
Biopsy Gleason 3+4 low-risk patients had PSA ≤10, clinical stage T1c-T2a, biopsy Gleason 3+4, 
and more than 8 cores taken on biopsy. 
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SUPPLEMENTARY MATERIAL:  
Table 2.2: Hazard ratios for risk of biochemical recurrence for biopsy Gleason 3+4 low risk 
group relative to D’Amico low-risk* group stratified by PSA density. 
 
Entry Criteria Number of 
D’Amico low 
risk patients 
Number of 
Gleason 7 low 
risk patients 
HR 95% CI p-value 
All 404 334 1.78 1.22 – 2.61 0.003 
≤ 0.30 ng/mL/g 372 299 1.70 1.13 – 2.58 0.012 
≤ 0.25 ng/mL/g 341 269 1.63 1.04 – 2.53 0.032 
≤ 0.20 ng/mL/g 289 219 2.28 1.38 – 3.76 0.001 
≤ 0.15 ng/mL/g 219 151 2.46 1.35– 4.51 0.003 
≤ 0.10 ng/mL/g 116 67 1.44 0.56– 3.70 0.451 
 
* D’Amico low-risk patients had PSA≤10, clinical stage T1c-T2a, biopsy Gleason ≤6, and more 
than 8 cores taken on biopsy.  
Biopsy Gleason 3+4 low-risk patients had PSA ≤10, clinical stage T1c-T2a, biopsy Gleason 3+4, 
and more than 8 cores taken on biopsy. 
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2.3          Appendix D: Detailed Methods 
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A. Regulatory Approval 
The research contained in the original manuscript was prepared under the auspices of the 
Durham Veterans Affairs (VA) Medical Center Research Institutional Review Board 
(protocol ID# 01827, “Predictors of Prostate Cancer and Prostate Cancer Outcomes in a 
National VA Cohort”). 
The supporting documentation for completion of this Master’s Paper was deemed exempt 
from Institutional Review Board approval by the Office of Human Research Ethics, 
University of North Carolina at Chapel Hill (study # 15-0718).   
B. Study Population 
1. Shared Equal Access Regional Cancer Hospital Database 
The Shared Equal Access Regional Cancer Hospital (SEARCH) Database 
is a national prostate cancer registry that includes retrospective data from 
consecutive prostate cancer patients at eight Veterans Administration (VA) 
medical centers (West Los Angeles, CA; Palo Alto, CA; San Diego, CA; San 
Francisco, CA; Augusta, GA; Birmingham, AL; Asheville, NC; and Durham, 
NC).    SEARCH includes detailed pre-operative clinical information, pathologic 
data, and follow-up information for >5000 men undergoing radical prostatectomy 
at these eight sites between 1982 and 2013.     
All data abstraction is performed using only medical record data from the 
Corporate Data Warehouse, VA Informatics and Computing Infrastructure 
(VINCI), and other VA sources.  Medical records are reviewed for data relevant 
to prostate cancer; no direct patient contact occurs.  Information from identified 
patients is recorded in an electronic database housed on VINCI and the VA 
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server.  The database and associated information is maintained behind the VA 
firewall.   
2. Inclusion Criteria for Study 
Men 18 years or older diagnosed with prostate cancer following an 
adequate prostate biopsy, defined as a minimum of 8 cores, and undergoing a 
radical prostatectomy using any surgical technique at five VA medical centers 
(Palo Alto, CA; West Los Angeles, CA; San Diego, CA; Durham, NC; and 
Augusta, GA) between January 1, 2001 and December 31, 2013 were combined 
into SEARCH.  These five centers were chosen based upon radical prostatectomy 
volume and the reliability of pathology results from these centers, as determined 
from previous studies.  A study start date of January 1, 2001 was selected as few 
men treated prior to this year had adequate prostate sampling at the time of 
biopsy.  The latest medical records complete data abstraction included 
information through December 31, 2013. 
To address our study question, we narrowed this large population of men 
with prostate cancer to those with low- to intermediate-risk disease characteristics 
diagnosed at the time of prostate biopsy (Appendix A, Table 1.1).  Specifically, 
we included men with a PSA ≤10.0 ng/mL, a Gleason score ≤7 (Appendix A, 
Table 1.2), and clinical stage T1c or T2a (Appendix A, Table 1.3).  As we sought 
to define a subset of men with pre-operatively defined intermediate-risk disease 
that had similar outcomes to men with low-risk disease, we further narrowed our 
eligible population to men with Gleason 3+4 or less disease diagnosed at the time 
of prostate biopsy, as primary Gleason 4 tumors are known to be an aggressive 
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subset of Gleason 7 prostate cancer with more advanced clinical and pathologic 
stages37 and higher rates of biochemical recurrence.30 
3. Exclusion Criteria for Study 
Men with missing data on our variables of interest were excluded from the 
study.  Our variables of interest included:  race, PSA, clinical stage, total number 
of prostate biopsy cores, number of positive prostate biopsy cores, Gleason score, 
radical prostatectomy pathologic information (Gleason score, positive margins, 
extracapsular extension, seminal vesicle invasion), surgical technique, and PSA 
density.  PSA density was explored in a subset analysis of the study, as >15% of 
men in the dataset were missing information on this variable.   
Additionally, men who received pre-operative hormonal or radiation 
therapy were excluded from the cohort, as these treatments prior to prostatectomy 
can affect pathologic Gleason grading.48   
C. Statistical Analysis 
We compared men who fulfilled the criteria of low-risk prostate cancer (clinical stage 
T1c/T2a, biopsy Gleason ≤6 and PSA ≤10 ng/mL)6-8 with the exception of biopsy Gleason 7 
(3+4) (henceforth “Gleason 7 low-risk”) versus men who met all 3 criteria for low-risk 
disease.  Once analyses were completed for all men meeting study inclusion criteria, 
increasingly strict definitions of low-volume disease were applied to the two groups.  The 
number or percentage of positive biopsy cores and PSA density were selected as ways to 
define low-volume disease; this selection was driven by the inclusion criteria of common 
active surveillance protocols for men with low-risk prostate cancer.33, 35, 36, 49   
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To assess if there was a cut-point of low volume disease with comparable outcomes 
among men with Gleason 7 low-risk disease and low-risk disease, all analyses evaluating 
differences in demographic and clinicopathologic variables, pathologic features, and 
biochemical recurrence between the two groups were repeated with matching of the 
percentage or number of positive biopsy cores or PSA density between them, including 
≤33% positive cores, ≤4 positive cores, ≤3 positive cores, and ≤2 positive cores, and PSA 
density ≤0.30, ≤0.25, ≤0.20, ≤0.15, and ≤0.10 ng/mL/g.  In total, we performed the analysis 
eleven times: 4 iterations limiting the groups by percentage or number of positive biopsy 
cores as compared to the entire cohort, and 5 times in a subset analysis limiting the groups by 
PSA density thresholds compared to the entire cohort with PSA density information.   
Statistical analyses were performed using Stata 13.1 (Stata, Corp., College Station, TX, 
USA).  Statistical significance was two-sided with p<0.05. 
1. Demographic and Clinicopathologic Variables 
Demographic factors of interest included patient age, year of surgery, and 
race.  In the SEARCH database, age and year of surgery are continuous variables, 
while race is a categorical variable defined as white, black, or other.  To begin, we 
assessed the distribution of the continuous variables in the dataset, patient age and 
surgery year, using histograms.  Patient age was normally distributed; thus, we 
reported mean age ± standard deviation in years.  We examined the difference in 
age between the Gleason 7 low-risk and D’Amico low-risk group using a t-test, as 
age was a normally distributed continuous variable in the dataset.  In contrast to 
age, surgery year was a non-normally distributed continuous variable, noted to be 
skewed left.  Accordingly, we reported the median year of surgery for each group, 
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along with the 25th and 75th percentiles.  As surgery year was a non-normally 
distributed continuous variable in the dataset, we examined the difference in year 
of surgery between the Gleason 7 low-risk and D’Amico low-risk group using a 
Wilcoxon rank-sum test.  To test the association of our categorical variable, race, 
across our low-risk and Gleason 7 low-risk patient populations, we used chi-
square tests.        
Clinicopathologic variables of interest included PSA, clinical stage, total 
number of biopsy cores and number of positive biopsy cores, surgical technique, 
pelvic lymph node dissection performance, pathological Gleason score, 
extracapsular extension, positive surgical margins, seminal vesicle invasion, 
positive pelvic lymph nodes, and length of follow-up.  To begin, we again 
assessed the distribution of our continuous variables of interest using histograms.  
PSA, total number of biopsy cores, number of positive biopsy cores, and length of 
follow-up were all non-normally distributed continuous variables that were 
skewed right in our patient sample.  Accordingly, we reported the median value 
for each variable with the 25th and 75th percentiles and examined differences 
between the Gleason 7 low-risk and D’Amico low-risk groups using the 
Wilcoxon rank-sum test.  Within SEARCH, surgical technique is classified into 
one of four categories (open radical retropubic prostatectomy, perineal 
prostatectomy, laparoscopic prostatectomy, and robotic assisted laparoscopic 
prostatectomy).  We classified pathological Gleason score into one of three 
categories (2-6, 3+4, and 4+3/8-10).  By study inclusion criteria, all men had 
clinical stage T1c or T2a prostate cancer.  The remaining clinicopathologic 
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variables of interest were binary variables, including pelvic lymph node dissection 
performance (completed or not completed), extracapsular extension (yes or no), 
positive surgical margins (yes or no), seminal vesicle invasion (yes or no), and 
positive pelvic lymph nodes (yes or no).  To test the association of these 
categorical variables across our low-risk and Gleason 7 low-risk patient 
populations, we used chi-square tests.  For any categorical variable with a cell 
count ≤5, we used Fisher’s exact test.      
2. Pathologic Features 
We used logistic regression models to test the association between risk 
group (Gleason 7 low-risk vs. D’Amico low-risk) and pathological features, 
including pathological Gleason score, positive surgical margins, extracapsular 
extension, and seminal vesicle invasion.  As previously noted, surgical margins, 
extracapsular extension, and seminal vesicle invasion are recorded as binary 
variables in SEARCH.  To enable logistic regression analysis, pathological 
Gleason score was categorized as ≤6 vs. ≥4+3.   
We used an exposure-disease logistic regression model, controlling for all 
variables that were unequally distributed among the men in our low-risk and 
Gleason 7 low-risk groups as well as variables known to be associated with 
pathologic outcomes.  The fully adjusted model included age at surgery, surgery 
year, race, number of biopsy cores, surgical center, surgical technique, clinical 
stage, and PSA (log-transformed).  While the number of positive biopsy cores was 
unevenly distributed between the groups on our initial analysis, which included all 
men in the cohort, we subsequently stratified by the maximum number of positive 
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biopsy cores and repeated analyses, thereby controlling for this potential 
confounder. 
3. Biochemical Recurrence 
Given the prolonged natural history of prostate cancer following radical 
prostatectomy,50 we evaluated the intermediate outcome of biochemical 
recurrence as our clinical endpoint of interest, rather than overall or prostate-
cancer specific survival.  Biochemical recurrence commonly triggers secondary 
treatment for prostate cancer post-prostatectomy, including salvage radiation 
and/or androgen deprivation therapy,8 and can significantly affect health-related 
quality of life.51-53  In SEARCH, biochemical recurrence is defined as a single 
PSA >0.2 ng/mL, two consecutive PSAs of 0.2 ng/mL, or secondary treatment for 
elevated PSA in the post-operative period.   
We analyzed the hazard ratios for biochemical recurrence between the 
Gleason 7 low-risk and D’Amico low-risk groups using Cox proportional hazards 
analysis.  Our final model included adjustment for the independent prognostic 
factors of age, surgery year, race, surgical center, surgical technique, clinical 
stage, PSA (log-transformed), and total number of prostate biopsy cores.     
We visually explored biochemical recurrence free survival using the 
Kaplan-Meier method and quantified the difference between our two groups using 
the log-rank test.   
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2.4          Appendix E: Strengths and Limitations 
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The primary strengths of our study stem from the reliability and thoroughness of our data 
source.  SEARCH is one of the premier multi-institutional prostate cancer databases in the 
world; researchers have generated over 100 peer-reviewed manuscripts from the database since 
2002.  Information within the database is exceptionally detailed, as access to patients’ complete 
medical records, including all physician notes, laboratory results, and imaging, is readily 
available.   
SEARCH captures all men diagnosed with prostate cancer in participating VA centers 
across the United States.  Accordingly, selection biases that may occur in single institutional 
registries are mitigated.  Access difficulties due to insurance or financial limitations that are 
encountered in private centers and limit the participation or follow-up of patients do not exist 
within the VA system, as the system is designed to be equal access.  Additionally, once a patient 
is within the system, the care that is delivered is independent of institutional or financial 
motivation, removing a potential for provider bias.  Finally, compared to other prostate cancer 
databases, SEARCH includes a large number of minority patients, increasing the external 
validity of research findings from the database. 
In order to maximize the reliability of our findings, we selected VA centers for study 
inclusion with known expertise in urologic care.  In recent years, many VA hospitals have been 
accused of providing substandard care and employing deficient physicians.54  As the reliability of 
our study results depends upon timely treatment following prostate biopsy and pre-operative 
staging, reproducible surgical results, detailed post-operative follow-up, and consistent pathology 
reporting, we chose five academically affiliated VA centers with strong reputations, fellowship-
trained urologic oncologists, and established pathologists on staff for study inclusion.   
67 
 
Our study has the inherent limitations of all retrospective analyses.  While our dataset 
included men from five VA centers, central pathology review was not completed.  As central 
pathology review may change biopsy Gleason score in up to 15% of cases, this introduces 
significant possible variation in our study.55  Changes in Gleason grading during our study 
period56 may limit study validity.  Pathologic findings serve as intermediate endpoints for 
aggressive disease and may not predict disease-specific or overall survival; overall survival was 
not included as few deaths occurred in the cohort.  Year of surgery and follow-up length between 
our low-risk and Gleason 7 low-risk groups were significantly different and introduce possible 
bias.  As SEARCH is a radical prostatectomy database, an inherent selection bias exists.  Finally, 
and most importantly, as all men with Gleason 3+4 low-risk in our dataset underwent radical 
prostatectomy, it is unknown if their outcomes with intervention reflect the natural history of 
Gleason 3+4 low-risk monitored on active surveillance.  Prospective study is required to address 
this limitation. 
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2.5          Appendix F: Study Implications 
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Prostate cancer is the most commonly diagnosed cancer among men in the developed world.1  
In the United States this year, an estimated 220,800 men will receive a new diagnosis of prostate 
cancer and 27,540 will die of the disease.2  An estimated 2.9 million American men are prostate 
cancer survivors.57  Active treatment for the newly diagnosed and follow-up care for prostate 
cancer survivors will cost the U.S. health care system approximately $14.1 billion dollars in 
2015.58 
Among men newly diagnosed with prostate cancer, approximately 90% will pursue definitive 
treatment (surgery or radiation therapy)3, 4 and the majority will experience at least one long-term 
adverse effect due to this treatment.5  The disease’s high incidence, tremendous costs, treatment 
morbidity, and long natural history have provoked extensive public health discussions on 
overdiagnosis and overtreatment.   
To reduce the overtreatment of low-risk prostate cancer,7 active surveillance protocols 
began in the late 1990’s.  On protocol, enrolled patients with low-risk prostate cancer are 
monitored with PSA testing every six months, an annual digital rectal exam, and a repeat 
prostate biopsy as frequently as every 12 months.  If worsening PSA kinetics, clinical stage 
progression on rectal exam, or changing biopsy characteristics are identified, then definitive 
treatment is advised.  With this management strategy, reported prostate cancer specific mortality 
is <1% among men on active surveillance protocols with long-term follow-up.9   
Active surveillance is a recommended treatment strategy for men with low-risk prostate 
cancer per National Comprehensive Cancer Network Guidelines.8  Limited and conflicting data 
exist on the outcomes of men with intermediate-risk prostate cancer,6-8 including Gleason 7 
disease, on active surveillance protocols.17, 18, 20, 38  As Gleason 7 disease is now the most 
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common score on prostate biopsy,10 we examined if a subset of Gleason 7 prostate cancer 
patients had similar outcomes to low-risk patients and thus could be reasonable potential active 
surveillance candidates.   
Using the SEARCH database of men undergoing radical prostatectomy between 2001 
and 2013, we compared men who fulfilled all three low-risk disease criteria6-8 to men with 
Gleason 7 prostate cancer who otherwise fulfilled the PSA and clinical stage low-risk disease 
criteria.  We explored associations between risk group, pathological features, and biochemical 
recurrence, with matching of PSA density (subset analysis) and the percentage or number of 
positive cores between the Gleason 7 low-risk and the D’Amico low-risk group.  We found that 
among men with PSA≤10 ng/mL and clinical stage T1c/T2a, those with Gleason 7 (3+4) PC in 
≤3 positive cores had similar rates of adverse pathology and biochemical recurrence as men with 
Gleason ≤6.   
Including men with Gleason 7 (3+4), PSA ≤10 ng/mL, clinical stage T1c/T2a, and ≤3 
total positive cores would considerably expand the population eligible for active surveillance.  
Approximately 6% of all men undergoing a radical prostatectomy from 2001-2013 at the five 
VA centers included in our study had Gleason 7 low-risk disease.  Interestingly, when studied 
over time, men with Gleason 7 low-risk disease comprise a growing percentage of the SEARCH 
database.  Since 2011, over 10% of men undergoing a radical prostatectomy in our centers had 
Gleason 7 low-risk disease with ≤3 total positive cores.  As our research indicates the 
pathological and biochemical recurrence outcomes of men with Gleason 7 low-risk disease are 
similar to those men with low-risk prostate cancer in our study population, inviting these men to 
monitor their disease on active surveillance may further reduce prostate cancer overtreatment.    
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As we created the Gleason 7 low-risk criteria for our study, the number of men nationally 
with prostate cancer meeting these criteria is unknown.  However, as Gleason 7 disease is the 
most commonly diagnosed prostate cancer score on biopsy,10 the likely increase in potential 
candidates for active surveillance with adoption of these criteria is significant.  As we strive to 
minimize prostate cancer overtreatment, continued retrospective study of outcomes among men 
with Gleason 7 disease undergoing definitive treatment, and careful prospective study of men 
with Gleason 7 disease on active surveillance protocols, is warranted. 
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